Moleculin Biotech (MBRX) News Today $3.52 +0.10 (+2.92%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 25 at 5:34 AM | americanbankingnews.comMoleculin Biotech (NASDAQ:MBRX) Research Coverage Started at StockNews.comJuly 16, 2024 | americanbankingnews.comMoleculin Biotech (NASDAQ:MBRX) Now Covered by Analysts at StockNews.comJuly 10, 2024 | prnewswire.comMoleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AMLJune 14, 2024 | prnewswire.comMoleculin Announces Additional Positive Preliminary Interim Data from AML Clinical TrialJune 12, 2024 | prnewswire.comMoleculin to Present at the Virtual Investor Pitch ConferenceJune 5, 2024 | prnewswire.comMoleculin to Participate in the Virtual Investor Lunch Break SeriesMay 16, 2024 | prnewswire.comMoleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid CongressMay 15, 2024 | prnewswire.comMoleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)May 14, 2024 | msn.comMoleculin Biotech, Inc. (NASDAQ:MBRX) Q1 2024 Earnings Call TranscriptMay 14, 2024 | finance.yahoo.comMoleculin Biotech Inc (MBRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ...May 13, 2024 | finanznachrichten.deMoleculin Biotech, Inc.: Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 13, 2024 | prnewswire.comMoleculin Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 10, 2024 | investorplace.comMBRX Stock Earnings: Moleculin Biotech Beats EPS for Q1 2024May 10, 2024 | markets.businessinsider.comMoleculin Biotech’s Annamycin Shows Promising Efficacy in AML Treatment, Backed by Strong Clinical Results and Buy RatingMay 9, 2024 | prnewswire.comMoleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for AnnamycinMay 8, 2024 | prnewswire.comMoleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and WebcastMay 7, 2024 | prnewswire.comMoleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject DataMay 2, 2024 | prnewswire.comMoleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024May 1, 2024 | prnewswire.comMoleculin Announces Formation of Scientific Advisory Board to Support Development of AnnamycinApril 26, 2024 | finanznachrichten.deJTC Team, LLC: Moleculin Biotech Participates in Virtual Investor "What This Means" Segment Hosted by JTC TeamApril 18, 2024 | markets.businessinsider.comMoleculin Biotech Says EMA Grants Orphan Drug Designation To Annamycin To Treat AMLApril 18, 2024 | prnewswire.comEuropean Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)April 12, 2024 | investing.comMoleculin Biotech Inc (MBRX)April 10, 2024 | markets.businessinsider.comMoleculin Biotech Reveals Positive Anti-cancer Data For Annamycin With Non-cardiotoxic EffectsApril 10, 2024 | prnewswire.comMoleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic PropertiesMarch 28, 2024 | finance.yahoo.comMoleculin to Present at the MedInvest Biotech & Pharma Investor ConferenceMarch 27, 2024 | finance.yahoo.comMoleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AMLMarch 27, 2024 | prnewswire.comMoleculin to Participate in the Virtual Investor Lunch Break: The Moleculin OpportunityMarch 26, 2024 | finance.yahoo.comMoleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2023 Earnings Call TranscriptMarch 25, 2024 | finanznachrichten.deMoleculin Biotech, Inc.: Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML TrialMarch 25, 2024 | marketbeat.comTrading was temporarily halted for "MBRX" at 10:03 AM with a stated reason of "LULD pause." Trading set to resume at 10:03 AM. March 25, 2024 | markets.businessinsider.comMoleculin Biotech Reports Positive Interim Data From MB-106 Phase 1B/2 Study In AMLMarch 25, 2024 | finance.yahoo.comMoleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML TrialMarch 23, 2024 | finanznachrichten.deMoleculin Biotech, Inc.: Moleculin Reports Full Year 2023 Financial ResultsMarch 22, 2024 | investorplace.comMBRX Stock Earnings: Moleculin Biotech Reported Results for Q4 2023March 22, 2024 | finance.yahoo.comMoleculin Biotech Inc Reports Fiscal Year 2023 Financial ResultsMarch 22, 2024 | prnewswire.comMoleculin Reports Full Year 2023 Financial ResultsMarch 22, 2024 | marketbeat.comTrading was temporarily halted for "MBRX" at 07:03 PM with a stated reason of "News pending."March 21, 2024 | investing.comMoleculin Biotech announces 1-for-15 reverse stock splitMarch 21, 2024 | benzinga.comA Preview Of Moleculin Biotech's EarningsMarch 20, 2024 | finanznachrichten.deMoleculin Biotech, Inc.: Moleculin Announces Reverse Stock SplitMarch 20, 2024 | prnewswire.comMoleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and WebcastMarch 19, 2024 | finance.yahoo.comMoleculin Announces Reverse Stock SplitMarch 12, 2024 | finance.yahoo.comMoleculin to Present at the 36th Annual ROTH ConferenceFebruary 6, 2024 | finance.yahoo.comHere's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn SituationJanuary 24, 2024 | finance.yahoo.comMoleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3December 21, 2023 | finance.yahoo.comMoleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-MarketDecember 15, 2023 | nasdaq.comHC Wainwright & Co. Initiates Coverage of Moleculin Biotech (MBRX) with Buy RecommendationDecember 14, 2023 | markets.businessinsider.comBuy Rating for Moleculin Biotech Amid Promising Annamycin Trial Results in AMLDecember 11, 2023 | markets.businessinsider.comMoleculin Presents Preliminary Efficacy Data Of Annamycin In Acute Myeloid Leukemia Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Prepare for a Recession Unlike Any Other (Ad)Dave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW. GET THE FREE GUIDE MBRX Media Mentions By Week MBRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MBRX News Sentiment▼0.960.62▲Average Medical News Sentiment MBRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MBRX Articles This Week▼31▲MBRX Articles Average Week Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: VCNX News Today AKTX News Today EQ News Today DARE News Today VYNE News Today ENLV News Today CLNN News Today RNXT News Today RVPH News Today LSTA News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MBRX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MBRX Stock Alerts